The US Food and Drug Administration (FDA) approved a label expansion for tirzepatide (Zepbound, Eli Lilly & Co) to include a four-dose single-patient-use KwikPen that delivers a full month of treatment in one device.
Patients with a valid prescription who opt for self-pay through LillyDirect can receive all doses of Zepbound in a KwikPen or single-dose vial, starting at $299 per month for the 2.5mg dose, the company reports.
Zepbound is available in 2.5mg, 5mg, 7.5mg, 10mg, 12.5mg, or 15mg doses. The 2.5mg is a starting dose and not an approved maintenance dose. The recommended maintenance doses are 5mg, 10mg, or 15mg injected subcutaneously once per week for weight reduction and long-term maintenance. The recommended maintenance doses are 10mg or 15mg for obstructive sleep apnea.
To learn more, visit Lilly.com/lillydirect/medicines/zepbound?device=kwikpen